International Organisations and Consortia

In 2017, MPP and the World Health Organization established the second three-year work plan as part of our official working relationship. The plan includes collaborating on a wide range of issues including: prioritising products for in-licensing quality assurance and patent transparency implementing the WHO treatment guidelines developing paediatric formulations (See GAP-f) preparing joint forecasts on the use of antiretroviral medicines in developing countries